Can Eye-Tracking reveal hidden brain risks in babies with sickle cell disease?

NCT ID NCT07721155

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

Sickle cell disease can affect brain development even in very young children. This study uses eye-tracking—a simple, non-invasive method—to measure attention and processing speed in infants aged 6 to 24 months. The goal is to identify those at highest risk for cognitive challenges early, so that supportive interventions can be started sooner.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could enable early detection of cognitive problems in children with sickle cell disease, allowing for timely interventions to support brain development.
What could go wrong
This is an observational study, not a treatment trial. It may not directly improve outcomes, and eye-tracking may not fully capture complex cognitive abilities.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROCOGNITION, CHILD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Amsterdam UMC

    Amsterdam, 1105AZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.